Delivery Order 36C24225D0064-36C24226N0463
Award Date 4/15/26
Potential Completion Date 4/14/27
Potential Value $624K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Sterling, VA, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Sofie CO., operating as IBA Molecular and headquartered in Sterling, Virginia, was awarded a $1.12 million firm fixed-price delivery order on April 15, 2025, to supply positron emission tomography (PET) radiopharmaceuticals to the Buffalo VA Medical Center through the Department of Veterans Affairs' Veterans Integrated Service Network 2. This delivery order, with an ultimate completion date of April 14, 2026, is issued under a larger $1.93 million indefinite delivery vehicle established in April...
- Veterans Integrated Service Network 4 awarded a purchase order to Sofie CO. (doing business as IBA Molecular) valued at $2,063,893.29 for F-18 radiopharmacy on June 30, 2022, with performance completion by June 29, 2027. Work is performed in Sterling, Virginia. The order is firm fixed-price with no set-aside designation. Sofie CO. is a for-profit subsidiary of Sofie Biosciences, Inc., specializing in radiopharmaceutical development and delivery, including PET imaging agents for cancer...
- On March 1, 2024, the Department of Veterans Affairs, through Veterans Integrated Service Network 16, awarded a delivery order valued at $235,810.76 to Sofie CO. (doing business as IBA Molecular) for the supply of radioactive positron emission tomography (PET) tracer isotopes to the Medical Center at the Veterans Integrated Service Network 16. This firm-fixed-price delivery order represents pricing year one activity under Indefinite Delivery Contract 36C25624D0046 and is scheduled for completion...
- This delivery order, awarded September 1, 2024, represents Option Year 2 of an existing contract vehicle with Sofie CO. (doing business as IBA Molecular), a Sterling, Virginia-based supplier of molecular diagnostics and therapeutic radiopharmaceuticals. The $194,870.88 firm fixed-price delivery order is funded by the Department of Veterans Affairs through Veterans Integrated Service Network 15 and is scheduled for completion by August 31, 2027. This award carries no set-aside designation and...
- Sofie CO., operating as IBA Molecular, received a delivery order award valued at $339.6K on January 22, 2026, for radioactive isotopes and positron emission tomography (PET) tracers supporting the Michael E. DeBakey VA Medical Center in Sterling, Virginia. This delivery order, with an ultimate completion date of February 28, 2027, is structured as a firm fixed-price contract with no set-aside designation. The award is issued under a larger indefinite delivery vehicle with VA Veterans...
- The Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded a $347,000.20 firm fixed-price purchase order to Sofie CO. (doing business as IBA Molecular) on January 20, 2026, for pet radiopharmaceutical services supporting the Nuclear Medicine Service at the Kent Community-Based Outpatient Clinic in Kent, Ohio. The contract, which carries no set-aside designation, has an ultimate completion date of January 19, 2027, and will be performed in Sterling, Virginia. This...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 2 (VA - VHA) awarded a $383,846.78 delivery order contract to Sofie CO., doing business as Sofie, a subsidiary of Sofie Biosciences, Inc., to provide PET radiopharmaceuticals. The firm fixed price contract runs from April 15, 2022 to April 15, 2023 and will be performed in Sterling, Virginia. PET radiopharmaceuticals are medical imaging radioisotopes that are used with positron emission...
- The Department of Veterans Affairs, Veterans Integrated Service Network 16 (VISN 16), awarded a $211,476.72 firm fixed-price purchase order to Sofie CO. (doing business as IBA Molecular) on October 1, 2023, for emergency isotopes with a completion date of December 31, 2023. The award carries no set-aside designation and is for performance at the contractor's Sterling, Virginia facility. Sofie CO., a for-profit subsidiary of Sofie Biosciences, Inc., specializes in the development, production, and...
- The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 10, awarded Sofie CO., operating as IBA Molecular, a $610,725.04 firm fixed-price purchase order on October 1, 2024, for PET MRI radiopharmaceuticals to support the John D. Dingell VA Medical Center in Detroit, Michigan. This award was issued without a set-aside designation following a sole source procurement notice published in September 2024. The VA determined that Sofie CO. was the only vendor capable of...
- Sofie CO., doing business as IBA Molecular, was awarded a $5.96 million firm fixed-price purchase order by Veterans Integrated Service Network 19 (VA VISN 19) on October 1, 2023, for the supply of positron emission tomography/computed tomography (PET/CT) radiopharmaceuticals through September 30, 2028. The contract was executed without set-aside designation and covers routine delivery of specialized imaging agents to support VA medical facilities, including F-18 fluorodeoxyglucose (FDG), F-18...
- 36C24225D0064Indefinite Delivery Contract
- 36C24225D0064-36C24226N0463Delivery Order
Veterans Integrated Service Network 2 issued a $642,466.40 delivery order to Sofie CO. (doing business as IBA Molecular) on April 15, 2026, for pet radiopharmaceuticals to Buffalo VA Medical Center, with performance expected to conclude by April 14, 2028. Place of performance is Sterling, VA. The order is firm fixed price with no set-aside designation. Sofie CO. specializes in the development and delivery of molecular diagnostics and therapeutic radiopharmaceuticals, with expertise in positron emission tomography imaging agents for cancer detection and neurological imaging.
Generated 7/2/26, 12:49 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Supplemental Agreement for work within scope | ($18k) | 4/13/26 | |
| Not listed | Not listed | $642.5k | 4/8/26 |